Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Zoreline (goserelin) 10.8 mg SC Implant in Prostate Cancer
2013-000799-14Phase 3Completed
- Sponsor
- Novalon S. A.
- Start
- Nov 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of goserelin in prostate cancer (PCa), sponsored by Novalon S. A. Primary endpoints: Testosterone suppression by Day 29 of Cycle 1 and Maintenance of testosterone suppression to Day 85 of Cycle 2. Started Nov 2014; status: completed.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2013-000799-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000799-14.